NEW YORK, Oct. 7, 2016 /PRNewswire/ -- Attorney Advertising
-- Bronstein, Gewirtz & Grossman, LLC is investigating
potential claims on behalf of purchasers of the securities of Ariad
Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA).
Such investors are advised to contact Peretz Bronstein or his investor relations
analyst Yael Hurwitz at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Ariad and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On October 6, 2016, The
Street published a report called "How Ariad Pharma Used a
Safety Problem to Jack Up a Cancer Drug's Price," in which it
described the conditions the Company used to up its price for the
leukemia drug Iclusig. The article continued to say that
after the U.S. Food and Drug Administration temporarily pulled
Iclusig from the market, it did allow Iclusig to go back on the
market with a reduced recommended dose and more restricted approved
use. Ariad then "embarked on a series of massive price increases"
for its now-niche drug, "instead of reducing its price tag to
reflect less benefit overall." Following this news, Ariad
stock dropped $0.52 per share, or
3.75%, to close at $13.35 on
October 6, 2016.
If you are aware of any facts relating to this investigation, or
purchased shares Ariad, you can assist this investigation by
visiting the firm's site: http://www.bgandg.com/aria. You can also
contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-ariad-pharmaceuticals-inc-aria-300341307.html
SOURCE Bronstein, Gewirtz & Grossman, LLC